$QURE

Balachandran Madhavan sold $278K of QURE

Balachandran Madhavan sold 10,000 shares of uniQure N.V. (QURE) at $27.85 ($0.28M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Balachandran Madhavan
Published Jun 17, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Bearish
medium confidence
Mentioned
$QURE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QUREBearishLow
01

Why it matters

A director’s open-market sale of $278.5k worth of shares is disclosed, with the transaction covered by a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not state reasons for the sale or whether other insiders/large holders acted; without accompanying operational news, signal quality is limited.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-17; sale dated 2026-06-15.

Background

The article is an SEC Form 4 insider transaction for uniQure N.V., reported by director Balachandran Madhavan.

Company-level read

Ticker impact

$QUREBearishMedium confidence
Context

uniQure N.V. director Balachandran Madhavan sold 10,000 shares in an open-market transaction on 2026-06-15 under a 10b5-1 plan.

Expected impact

Near-term impact likely muted; any reaction may fade unless accompanied by other catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but the sale is explicitly under a pre-arranged 10b5-1 plan, reducing interpretability versus discretionary selling.

Market effects

No direct sector read-through; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

10b5-1 sales often reflect scheduled liquidity needs rather than negative fundamentals, so the market may overreact initially.

Key entities

  • uniQure N.V.

    Company whose director insider sale is disclosed on SEC Form 4.

  • Balachandran Madhavan

    Director who sold 10,000 shares at $27.85/share on 2026-06-15 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.